论文部分内容阅读
EMA/CO方案是指每两周一程应用足叶乙甙-氨甲喋呤-放线菌素D-环磷酰胺-长春新碱(e-toposide-methotrexate-actinomycinD and Cytoxan-Oncovin)Charing Cross医院用于高危滋养细胞疾病(gestational trophoblastic disease,GTD)的化疗,报道的存活率为84％。另有相近的报道EMA/CO方案的完全反应率为77％～94％,存活率为82％～100％。EMA/CO方案用其疗效显著而毒性小已成为治疗高危GTD的首先方案。代替了MAC方案
The EMA / CO regimen refers to the use of etoposide-methotrexate-dactinomycin D-cyclophosphamide-vincristine (Chapman) at the Charing Cross hospital every two weeks for high-risk Chemotherapy of gestational trophoblastic disease (GTD) reported a survival rate of 84%. Another similar report EMA / CO regimen complete response rate of 77% to 94%, the survival rate of 82% to 100%. EMA / CO regimen with its significant effect and low toxicity has become the first treatment of high-risk GTD program. Replace the MAC program